Study to Investigate the Efficacy and Safety of Apomivir®
Status:
Unknown status
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
Apomivir® is extracted from a proprietary spirulina strain, FEM-101, a kind of blue
cyanobacterium with patented freeze-thaw lysis and extraction method. According to the
preclinical studies, Apomivir® have been proven to have excellent broad-spectrum anti-viral
ability, especially for seasonal influenza viruses (Influenza virus A and B) that may cause
illness, paralysis and even death, especially in children and elderly people. This phase II
study is designed to evaluate the efficacy and safety of Apomivir® (120 mg b.i.d.) in
subjects with seasonal influenza.